Please assess the completion status of the following clinical trial:

Trial Title: Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allogeneic transplant within the prior 1 year~* Age greater than or equal to 18 years~* Capable of informed consent~* Neutrophil engraftment has occurred~* This is the first clinically-recognized episode of viral respiratory tract infection after transplant~Exclusion Criteria:~* Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing pneumonia~* CMV, VZV or HSV pneumonia~* Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication (ex: BO, COP)~* Treating physician believes the risk of systemic steroids is too great~* Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent dose of another steroid~* Currently receiving pentostatin~* Mycophenolate initiated de novo or increased within the past 4 weeks~* Use of inhaled corticosteroids within the past 2 weeks for at least 1 week~* Haploidentical or T-cell depleted graft~* Lack of pre-transplant pulmonary function tests~* Evidence of a prior symptomatic viral respiratory tract infection following transplant, whether treated or not~* Allergy or adverse reaction to any of the study drugs~* Relapse or progression of the underlying malignancy~* Palliative care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
- SAMS (Type: EXPERIMENTAL): Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).

Based on this trial design, predict the completion outcome and termination type (if applicable).